Forbedring i ADHD-kjernesymptomer med atomoksetin versus metylfenidat: en metaanalyse av direkte sammenlikninger

Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis

Authors
Hazell, P. L. Kohn, M. R. Dickson, R. Walton, R. J. Granger, R. E. Wyk, G. W.
Year
2011
Journal
Journal of Attention Disorders
Volume
15
Pages
674-83
OBJECTIVE: Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal. This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents. METHOD: Selection criteria included randomized, controlled design; duration 6 weeks; and assessment of ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS) scores. Six-week response rates, defined as >40% reduction in ADHDRS total score, were compared using a noninferiority margin of -15%. RESULTS: Seven studies met inclusion criteria (N = 1,368). After 6 weeks, 53.6% (95% confidence interval [CI] 48.6%-58.4%) of atomoxetine-treated patients (n = 811) had responded compared with 54.4% (47.6%-61.1%) for methylphenidate (n = 557), with atomoxetine demonstrating noninferiority to methylphenidate (absolute difference -0.9%, 95% CI -9.2%-7.5%). CONCLUSION: After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents.

Oversett med Google Translate
-
Type of intervention

Treatment and Child Welfare Interventions

Topic

Mental Health Problems and Disorders

ADHD

Intervention

Pharmacological Treatment

Stimulants

Age group

School Aged Children (6-12 years)

Adolescents (13-18 years)

Age not specified

More information
Looking for more information on this topic? Click on the links below to search PsykTestBarn and Håndboka